Mereo BioPharma Group PLC ADR (MREO) Stock Analysis

Mereo BioPharma Group PLC ADR (MREO) is a publicly traded company in the HEALTHCARE sector. It trades at $0.34, carries a market capitalization of $49.13M. This page summarizes the public market data, fundamentals, and frequently asked questions for MREO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Mereo BioPharma Group PLC ADR currently has a Bearish sentiment score of -0.30.

About Mereo BioPharma Group PLC ADR

Mereo BioPharma Group PLC is a biopharmaceutical company based in London, dedicated to advancing innovative therapeutics for oncology and rare diseases. With a strategic focus on addressing unmet medical needs, Mereo is developing a diverse pipeline of novel treatments aimed at significantly improving patient outcomes. The company leverages its clinical development expertise and a strong portfolio to position itself effectively within the competitive biopharmaceutical sector, thereby enhancin...

GNG Research Analysis

GNG Research scores Mereo BioPharma Group PLC ADR (MREO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MREO.

Frequently Asked Questions

Does MREO pay dividends?

Mereo BioPharma Group PLC ADR (MREO) does not currently pay a regular dividend.

What is MREO's market cap?

Mereo BioPharma Group PLC ADR (MREO) has a market capitalization of $49.13M with a current stock price of $0.34.